Evotec SE today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-venture-capital-consortium-form-breakpoint-therapeutics-gmbh-5831
Evotec completes acquisition of Just Biotherapeutics
Evotec SE today announced that the strategic transaction to acquire Just Biotherapeutics (“Just.Bio”), signed on 20 May 2019, has been completed. The acquisition accelerates Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation, strengthening Evotec’s multimodality approach to R&D. Evotec acquired Just.Bio to integrate their cutting-edge machine-learning technologies and agile, flexible methods for the design, development, and manufacturing of biologics into Evotec’s drug discovery offerings. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-completes-acquisition-of-just-biotherapeutics-5829
Just Biotherapeutics and Teva enter an agreement for the design and development of a high productivity (HP) biomanufacturing process
Just Biotherapeutics, Inc., an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just-biotherapeutics-and-teva-enter-an-agreement-for-the-design-and-development-of-a-high-productivity-hp-biomanufacturing-process-5827
Evotec SE places first Schuldschein (Promissory note) worth € 250 m
Evotec SE announced today that the Company successfully issued a Schuldschein (promissory note) of € 250 m on the capital market. The Schuldschein was placed with a fixed and variable interest rate of on average below 1.5 percent over 3, 5, 7, and 10 years maturity. Following high demand from debt investors, which led to a significant oversubscription of the order book and attractive credit spreads, the initial target volume of € 100 m could be successfully increased to € 250 m. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-places-first-schuldschein-promissory-note-worth-eur-250-m-5825
Evotec, Sensyne Health, the University of Oxford, OSI, and OUI create new bridge partnership “LAB10x” in digital health
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university’s research commercialisation company), and Oxford Sciences Innovation (“OSI”, the world’s largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-sensyne-health-the-university-of-oxford-osi-and-oui-create-new-bridge-partnership–lab10x-in-digital-health-5823
Resolutions of the Annual General Meeting 2019 of Evotec SE
Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2019 with very strong supporting majorities. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/resolutions-of-the-annual-general-meeting-2019-of-evotec-se-5821
New LAB150 project identified
MaRS Innovation has announced the launch of a fifth project to be developed under the BRIDGE LAB150, a partnership between Evotec SE and MaRS Innovation. The aim of the project is to develop a novel rapid-acting antidepressant with the potential to provide patient relief much faster than conventional treatments. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/new-lab150-project-identified-5820
Evotec receives $ 23.8 m grant to join the global fight against tuberculosis
Evotec SE today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives–238-m-grant-to-join-the-global-fight-against-tuberculosis-5817
Evotec and Celgene further expand iPSC collaboration including new cell type
Evotec SE announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-further-expand-ipsc-collaboration-including-new-cell-type-5815
Evotec publishes DDup 8: Evotec’s unique iPSC-based drug discovery platform
The 8th edition of DDup is dedicated to our highly innovative iPSC platform, which we started developing more than six years ago with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach highest industrial standards. Today, it represents one of the largest and most sophisticated iPSC platforms in the industry. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-8-evotecs-unique-ipsc-based-drug-discovery-platform-5813